August 2022 Content Release Copied
Clinical Profile Documentation
AJCC 8th Edition Staging
This release contains updated TNM values, Stage Groupings, and Template functionality for:
- Fallopian Tube Cancer
- Ovarian Cancer
- Primary Peritoneal Cancer
Users will see updates to the Distant Metastasis (M) documentation points for Ovarian cancer, Primary Peritoneal cancer, and Fallopian Tube cancer:
- cM1a is no longer available
- cM1 and pM1 are available and valid when the M1 subcategory is not specified
The new content does not affect previous charting documented on existing patients. All previous charting is brought forward during a subsequent visit, just as it did prior to this release.
Biomarker Guidance
A new informational row called BIOMARKER TESTING will display NCCN biomarker testing guidelines for non-small cell lung cancer in the Details section, when adding a new Problem in a patient’s Clinical Profile. This information can be used to place biomarker testing in the Orders tab.
This feature is part of an effort to support biomarker testing and optimize your patients’ treatment plans in iKnowMed.
Problems
Additions
The following items are available for documentation in Problems and appear in the Charge Capture Report (CCR). Additional ICD-10 codes* may be displayed to present the surrounding nodes.
- Castleman’s disease
Please see APPENDIX A for a complete summary of changes.
Updates
The Problems > Add Details area is updated with applicable documentation points for the following diagnoses:
Oropharyngeal Cancer, Human Papilloma no longer contains the following documentation point:
- HPV-18 positive
Myelofibrosis has been assigned a pathway (PW) designation to ensure documentation remains synonymous with clinical decision support and ICD-10 mapping. The following problems now have PW to the left of the problem in the search results:
- Acute myelofibrosis (disorder)
- Acute panmyelosis w myelofibrosis, in relapse
- Acute panmyelosis w myelofibrosis, in remission
- Congenital neutropenia, myelofibrosis, nephromegaly syndrome
- Ischaemic myelofibrosis
- Myelofibrosis
- Myelofibrosis caused by drug
- Myelofibrosis due to and following essential thrombocytopenia
- Myelofibrosis due to and following polycythemia vera
- Myelofibrosis w myeloid metaplasia
- Secondary myelofibrosis
Billing & HCPCS Codes
Updates
Bortezomib Billing Guidance – Per CMS, the HCPCS billing code for Bortezomib has changed to J3490 backdating to the first of July. The code is now available but may not generate on charge capture. If you find the billing code is incorrect, billing considerations can be used. Please use billing considerations for this brand only:
- Reddy’s Laboratories, Inc., NDC 43598086560
Lab Analytes and Panels
Additions
- ANA screen w/ reflex to titer
- Cabot rings WAM
- CMI173-PD-1 panel
- Coarse speckled
- COVID/Flu/RSV panel
- reticular (MITO)
- Dense fine speckled
- Discrete nuclear dots
- Influenza A, PCR
- Influenza B, PCR
- Insulin panel
- Insulin, 120 minutes post dose
- Insulin, 30 minutes post dose
- Insulin, 60 minutes post dose
- Insulin, 90 minutes post dose
- Insulin, fasting
- Invitae adenomatous polyposis panel
- Invitae adenomatous polyposis results
- Invitae chronic pancreatitis panel + Invitae multi-cancer panel
- Invitae chronic pancreatitis panel + Invitae multi-cancer panel results
- Invitae ehlers-danlos syndrome panel + Invitae marfan syndrome test
- Invitae ehlers-danlos syndrome panel + Invitae marfan syndrome test result
- Invitae multi-cancer panel + GALNT12 + RNF43 + RPS20
- Invitae multi-cancer panel + Invitae BRCA1/2 panel
- Invitae multi-cancer panel + Invitae BRCA1/2 panel results
- Invitae multi-cancer panel + Invitae familial adenomatous polyposis test
- Invitae multi-cancer panel + Invitae familial adenomatous polyposis test result
- Invitae multi-cancer panel + MC1R
- Invitae multi-cancer panel + MC1R results
- Luteinizing hormone, IU/L
- Rapid SARS-COV-2, PCR
- Rh(D) genotype
- RSV, PCR
- SARS-COV-2 CT value
- Transcriptome detection_v1 panel, hybrid
Medications
Additions
- BDTX-1535 invest Oral
- DZD9008 invest Oral
- JANX007 invest IV
- LP035 invest Buccal Film
- MTB-9655 invest Oral
- Nature Throid Oral
- PF-07265028 invest Oral
- PRT811 invest Oral
- Q901 invest IV
- SIM1811-03 invest IV
- Troriluzole (BHV-4157) invest Oral
- TU2218 invest Oral
- Tusamitamab Ravtansine invest (SAR408701 invest IV)
- VT1021 invest IV
- XmAb20717 invest IV
- Zimberelimab invest (AB122 invest IV)
Updates
| Medication | Update |
| ABI-009 invest IV | New Brand-name available: Nab-sirolimus invest (ABI- 009 invest IV) |
| Skyrizi (Risankizumab-rzaa IV) | New default Sig: Risankizumab-rzaa 600 mg intravenously Piggyback once; Dilute with 100-500 mL D5W to a final concentration 1.2-6 mg/mL. Administer over at least 1 hour. Complete infusion within 8 hours of dilution. Do not administer with other agents. Do not shake.
Updated Max Single Dose: 600 mg |
| NC318 invest IV | New Form available: 400 mg recon soln |
| Abemaciclib invest (LY2835219 invest Oral) | New Form(s) available:
|
| Palbociclib invest Oral | New Forms available:
|
| Vinblastine IV | Updated Max Single Dose: 17 mg |
| Elacestrant invest (RAD1901 invest Oral) | New Instructions available: IP must be stored at controlled room temperature 20-25 degree C (68- 77degree F).
New Frequency available: daily |
| Pemetrexed IV | New default Sig: 500 mg/m2 intravenously Piggyback once; administer over 10 minutes; Dilute with NS to a total volume of 100 mL. |
| Sasanlimab invest Subcutaneous | New Sig available: 300 mg subcutaneously every 4 weeks |
Regimens
This section does not include clinical trial regimens.
Biosimilar and Reference Regimens
To improve ease of ordering, the Collaborative Care Committee (CCC) recently voted to merge separate biosimilar and reference regimens into single regimen templates. These updates will occur in a rolling fashion over the next several months.
This release contains the consolidation of all bevacizumab regimen templates and the addition of a new bevacizumab biosimilar (Alymsys). For a list of all merged bevacizumab regimens please refer to APPENDIX B.
Additions
| Regimen Name | Diagnosis |
| Bendamustine (90 mg/m2) D1,2 Q28D (CAR T- cell Therapy Lymphodepletion) | Leukemia, Acute Lymphocytic (ALL), Lymphoma, Non-Hodgkin (NHL) (Parent), Multiple Myeloma (MM) |
| Docetaxel + Abiraterone + Prednisone + ADT Q3M (Abiraterone + Prednisone + Goserelin only) | Prostate Cancer |
| Docetaxel + Abiraterone + Prednisone + ADT Q3M (Abiraterone + Prednisone + Leuprolide only) | Prostate Cancer |
| Docetaxel + Darolutamide + ADT Q3M (Darolutamide + Goserelin only) | Prostate Cancer |
| Docetaxel + Darolutamide + ADT Q3M (Darolutamide + Leuprolide only) | Prostate Cancer |
| FOLFIRINOX + Panitumumab Q14D | Colon Cancer, Rectal Cancer |
| Ibrutinib (3 cycles) fb Ibrutinib + Venetoclax Q28D (12 cycles) (CLL) | Leukemia, Chronic Lymphocytic (CLL), Lymphoma, Non-Hodgkin (NHL) (Parent) |
| Obinutuzumab + Lenalidomide D1-21 Q28D | Lymphoma, Non-Hodgkin (NHL) (Parent) |
| Risankizumab-rzza IV D1,28,56 (Crohn’s Induction) | Crohn’s Disease |
Updates
Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference updates, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.
- Brain Tumor (Parent)
- Cervical Cancer
- Colon Cancer
- Fallopian Tube Cancer
- Hepatocellular Carcinoma (HCC)
- Lung Cancer, Non-small Cell (NSCLC)
- Malignant Mesothelioma
- Malignant Pleural Mesothelioma
- Ovarian and Primary Peritoneal Cancer
Research
- Rectal Cancer
- Renal Cell Carcinoma (RCC)
- Uterine Cancer (Parent)
Updates
The USOR Clinical Trials listed in the table below are updated:
| Updated Reference Information | Updated Drug Service Order Information | Updated Regimen Instructions | Other Changes | |
| USOR 16104 | X | |||
| USOR 18126 | X | |||
|
USOR 18283 |
X |
No longer available:
|
||
| USOR 19113 | X | X | ||
|
USOR 20136 |
Now available:
No longer available:
|
|||
| USOR 20138 | X | X | ||
| USOR 20175 | X | X | X | |
| USOR 20176 | X | |||
| USOR 20189 | X | |||
| USOR 20229 | X | |||
| USOR 20363 | X | X | ||
| USOR 20388 | X | |||
| USOR 20398 | X | X | Now available:
|
|
| USOR 20409 | X | X | X | |
| USOR 21171 | X | X | X | |
| USOR 21219 | X | X | X | |
| USOR 21235 | X | X | ||
| USOR 21239 | X | X | X | |
|
USOR 21326 |
X |
X |
No longer available:
|
|
| USOR 21346 | X | X | X | Now available:
|
| USOR 21378 | X | |||
| USOR 21536 | X | |||
| USOR 21537 | X |
Appendix A
Problem & Codes Summary
| Problem | ICD-10 Code(s)* |
| Abdominal distension (gaseous) | R14.0 Abdominal distension (gaseous) |
| Abnormal bleeding of cervix | N88.8 Other specified noninflammatory disorders of cervix uteri |
| Abnormal findings on diagnostic imaging of gastrointestinal tract | R93.3 Abnormal findings on diagnostic imaging of other parts of digestive tract |
| Abscess of breast (disorder) | N61.1 Abscess of the breast and nipple |
| Abscess of ischiorectal fossa | K61.39 Other ischiorectal abscess |
| Abscess of liver (disorder) | K75.0 Abscess of liver |
| Abscess of lower limb (disorder) | L02.415 Cutaneous abscess of right lower limb L02.416 Cutaneous abscess of left lower limb L02.419 Cutaneous abscess of limb, unspecified |
| Abscess of nipple (disorder) | N61.1 Abscess of the breast and nipple |
| Acute anal fissure (disorder) | K60.0 Acute anal fissure |
| Acute appendicitis (disorder) | K35.80 Unspecified acute appendicitis |
| Acute appendicitis without peritonitis (disorder) | K35.80 Unspecified acute appendicitis |
| Acute duodenal ulcer with hemorrhage (disorder) | K26.0 Acute duodenal ulcer with hemorrhage |
| Acute gastric ulcer (disorder) | K25.0 Acute gastric ulcer with hemorrhage K25.1 Acute gastric ulcer with perforation
K25.2 Acute gastric ulcer with both hemorrhage and perforation K25.3 Acute gastric ulcer without hemorrhage or perforation |
| Acute gastritis with bleeding | K29.01 Acute gastritis with bleeding |
| Anal polyp (disorder) | K62.0 Anal polyp |
| Anal skin tag (disorder) | K64.4 Residual hemorrhoidal skin tags |
| Anal spasm (disorder) | K59.4 Anal spasm |
| Anogenital molluscum contagiosum | B08.1 Molluscum contagiosum |
| Anorectal fistula (disorder) | K60.5 Anorectal fistula |
| Appendicitis (disorder) | K37 Unspecified appendicitis |
| ASC-H pap smear | R87.611 Atypical squamous cells cannot exclude high grade squamous intraepithelial lesion on cytologic smear of cervix (ASC-H) |
| ASC-US pap smear | R87.610 Atypical squamous cells of undetermined significance on cytologic smear of cervix (ASC-US) |
| Barium enema abnormal (finding) | R93.3 Abnormal findings on diagnostic imaging of other parts of digestive tract |
| Benign neoplasm of anal canal (disorder) | D12.9 Benign neoplasm of anus and anal canal |
| Benign neoplasm of anus (disorder) | D12.9 Benign neoplasm of anus and anal canal |
| Benign neoplasm of appendix (disorder) | D12.1 Benign neoplasm of appendix |
| Benign neoplasm of ascending colon (disorder) | D12.2 Benign neoplasm of ascending colon |
| Benign neoplasm of colon (disorder) | D12.6 Benign neoplasm of colon, unspecified |
| Benign neoplasm of descending colon disorder) | D12.4 Benign neoplasm of descending colon |
| Benign neoplasm of perianal skin (disorder) | D23.5 Other benign neoplasm of skin of trunk |
| Benign neoplasm of sigmoid colon (disorder) | D12.5 Benign neoplasm of sigmoid colon |
| Bilateral inguinal hernia (disorder) | K40.00 Bilateral inguinal hernia, with obstruction, without gangrene, not specified as recurrent K40.01 Bilateral inguinal hernia, with obstruction, without gangrene, recurrent
K40.10 Bilateral inguinal hernia, with gangrene, not specified as recurrent K40.11 Bilateral inguinal hernia, with gangrene, recurrent K40.20 Bilateral inguinal hernia, without obstruction or gangrene, not specified as recurrent K40.21 Bilateral inguinal hernia, without obstruction or gangrene, recurrent |
| Candidiasis of nails (disorder) | B37.2 Candidiasis of skin and nail |
| Candidiasis of skin (disorder) | B37.2 Candidiasis of skin and nail |
| Carcinoid syndrome (disorder) | E34.0 Carcinoid syndrome |
| Castleman’s disease (disorder) | D47.Z2 Castleman disease |
| Cellulitis (disorder) | L03.90 Cellulitis, unspecified |
| Cervical intraepithelial neoplasia grade 2 (disorder) | N87.1 Moderate cervical dysplasia |
| Cholecystitis (disorder) | K81.9 Cholecystitis, unspecified |
| Cholesterolosis of gallbladder (disorder) | K82.4 Cholesterolosis of gallbladder |
| Chronic cholecystitis (disorder) | K81.1 Chronic cholecystitis |
| Chronic gastric ulcer (disorder) | K25.4 Chronic or unspecified gastric ulcer with hemorrhage
K25.5 Chronic or unspecified gastric ulcer with perforation K25.6 Chronic or unspecified gastric ulcer with both hemorrhage and perforation K25.7 Chronic gastric ulcer without hemorrhage or perforation |
| Chronic gastric ulcer with hemorrhage (disorder) | K25.4 Chronic or unspecified gastric ulcer with hemorrhage |
| Chronic pancreatitis NOS | K86.1 Other chronic pancreatitis |
| Chronic ulcerative pancolitis (disorder) | K51.00 Ulcerative (chronic) pancolitis without complications
K51.011 Ulcerative (chronic) pancolitis with rectal bleeding K51.012 Ulcerative (chronic) pancolitis with intestinal obstruction K51.013 Ulcerative (chronic) pancolitis with fistula K51.014 Ulcerative (chronic) pancolitis with abscess K51.018 Ulcerative (chronic) pancolitis with other complication K51.019 Ulcerative (chronic) pancolitis with unspecified complications |
| Chronic ulcerative proctitis (disorder) | K51.20 Ulcerative (chronic) proctitis without complications
K51.211 Ulcerative (chronic) proctitis with rectal bleeding K51.212 Ulcerative (chronic) proctitis with intestinal obstruction K51.213 Ulcerative (chronic) proctitis with fistula K51.214 Ulcerative (chronic) proctitis with abscess K51.218 Ulcerative (chronic) proctitis with other complication K51.219 Ulcerative (chronic) proctitis with unspecified complications |
| Closed fracture of left forearm (disorder) | S52.92XA Unspecified fracture of left forearm, initial encounter for closed fracture
S52.92XD Unspecified fracture of left forearm, subsequent encounter for closed fracture with routine healing S52.92XG Unspecified fracture of left forearm, subsequent encounter for closed fracture with delayed healing S52.92XK Unspecified fracture of left forearm, subsequent encounter for closed fracture with nonunion S52.92XP Unspecified fracture of left forearm, subsequent encounter for closed fracture with malunion S52.92XS Unspecified fracture of left forearm, sequela |
| Closed fracture of multiple ribs (disorder) | S22.41XA Multiple fractures of ribs, right side, initial encounter for closed fracture
S22.41XD Multiple fractures of ribs, right side, subsequent encounter for fracture with routine healing S22.41XG Multiple fractures of ribs, right side, subsequent encounter for fracture with delayed healing S22.41XK Multiple fractures of ribs, right side, subsequent encounter for fracture with nonunion S22.41XS Multiple fractures of ribs, right side, sequela S22.42XA Multiple fractures of ribs, left side, initial encounter for closed fracture S22.42XD Multiple fractures of ribs, left side, subsequent encounter for fracture with routine healing S22.42XG Multiple fractures of ribs, left side, subsequent encounter for fracture with delayed healing S22.42XK Multiple fractures of ribs, left side, subsequent encounter for fracture with nonunion S22.42XS Multiple fractures of ribs, left side, sequela S22.43XA Multiple fractures of ribs, bilateral, initial encounter for closed fracture S22.43XD Multiple fractures of ribs, bilateral, subsequent encounter for fracture with routine healing S22.43XG Multiple fractures of ribs, bilateral, subsequent encounter for fracture with delayed healing S22.43XK Multiple fractures of ribs, bilateral, subsequent encounter for fracture with nonunion S22.43XS Multiple fractures of ribs, bilateral, sequela S22.49XA Multiple fractures of ribs, unspecified side, initial encounter for closed fracture S22.49XD Multiple fractures of ribs, unspecified side, subsequent encounter for fracture with routine healing S22.49XG Multiple fractures of ribs, unspecified side, subsequent encounter for fracture with delayed healing S22.49XK Multiple fractures of ribs, unspecified side, subsequent encounter for fracture with nonunion S22.49XS Multiple fractures of ribs, unspecified side, sequela |
| Closed fracture of neck of femur (disorder) | S72.001A Fracture of unspecified part of neck of right femur, initial encounter for closed fracture
S72.001D Fracture of unspecified part of neck of right femur, subsequent encounter for closed fracture with routine healing S72.001G Fracture of unspecified part of neck of right femur, subsequent encounter for closed fracture with delayed healing S72.001K Fracture of unspecified part of neck of right femur, subsequent encounter for closed fracture with nonunion S72.001P Fracture of unspecified part of neck of right femur, subsequent encounter for closed fracture with malunion S72.002A Fracture of unspecified part of neck of left femur, initial encounter for closed fracture S72.002D Fracture of unspecified part of neck of left femur, subsequent encounter for closed fracture with routine healing S72.002G Fracture of unspecified part of neck of left femur, subsequent encounter for closed fracture with delayed healing S72.002K Fracture of unspecified part of neck of left femur, subsequent encounter for closed fracture with nonunion S72.002P Fracture of unspecified part of neck of left femur, subsequent encounter for closed fracture with malunion S72.002S Fracture of unspecified part of neck of left femur, sequela S72.009A Fracture of unspecified part of neck of unspecified femur, initial encounter for closed fracture S72.009D Fracture of unspecified part of neck of unspecified femur, subsequent encounter for closed fracture with routine healing S72.009G Fracture of unspecified part of neck of unspecified femur, subsequent encounter for closed fracture with delayed healing S72.009K Fracture of unspecified part of neck of unspecified femur, subsequent encounter for closed fracture with nonunion S72.009P Fracture of unspecified part of neck of unspecified femur, subsequent encounter for closed fracture with malunion S72.009S Fracture of unspecified part of neck of unspecified femur, sequela |
| Closed fracture of right forearm (disorder) | S52.91XA Unspecified fracture of right forearm, initial encounter for closed fracture
S52.91XD Unspecified fracture of right forearm, subsequent encounter for closed fracture with routine healing S52.91XG Unspecified fracture of right forearm, subsequent encounter for closed fracture with delayed healing S52.91XK Unspecified fracture of right forearm, subsequent encounter for closed fracture with nonunion S52.91XP Unspecified fracture of right forearm, subsequent encounter for closed fracture with malunion S52.91XS Unspecified fracture of right forearm, sequela |
| Clostridial enteric disease (disorder) | A04.71 Enterocolitis due to Clostridium difficile, recurrent
A04.72 Enterocolitis due to Clostridium difficile, not specified as recurrent |
| Colostomy malfunction (disorder) | K94.03 Colostomy malfunction |
| Colostomy status | Z93.3 Colostomy status |
| Concussion with no loss of consciousness (disorder) | S06.0X0A Concussion without loss of consciousness, initial encounter
S06.0X0D Concussion without loss of consciousness, subsequent encounter S06.0X0S Concussion without loss of consciousness, sequela |
| Condyloma latum (disorder) | A51.31 Condyloma latum |
| Contusion of lower back (disorder) | S30.0XXA Contusion of lower back and pelvis, initial encounter
S30.0XXD Contusion of lower back and pelvis, subsequent encounter S30.0XXS Contusion of lower back and pelvis, sequela |
| Contusion of pelvic region (disorder) | S30.0XXA Contusion of lower back and pelvis, initial encounter
S30.0XXD Contusion of lower back and pelvis, subsequent encounter S30.0XXS Contusion of lower back and pelvis, sequela |
| Contusion of scalp (disorder) | S00.03XA Contusion of scalp, initial encounter S00.03XD Contusion of scalp, subsequent encounter S00.03XS Contusion of scalp, sequela |
| Crohn’s disease of small intestine with rectal bleeding | K50.011 Crohn’s disease of small intestine with rectal bleeding |
| Cuff dehiscence | T81.30XA Disruption of wound, unspecified, initial encounter
T81.30XD Disruption of wound, unspecified, subsequent encounter T81.30XS Disruption of wound, unspecified, sequela |
| Cutaneous abscess of abdominal wall | L02.211 Cutaneous abscess of abdominal wall |
| Cutaneous abscess of left upper limb | L02.414 Cutaneous abscess of left upper limb |
| Cutaneous abscess of neck | L02.11 Cutaneous abscess of neck |
| Cutaneous abscess of right upper limb | L02.413 Cutaneous abscess of right upper limb |
| Dehydration (disorder) | E86.0 Dehydration |
| Diaphragmatic hernia (disorder) | K44.0 Diaphragmatic hernia with obstruction, without gangrene
K44.1 Diaphragmatic hernia with gangrene K44.9 Diaphragmatic hernia without obstruction or gangrene |
| Diaphragmatic hernia with gangrene (disorder) | K44.1 Diaphragmatic hernia with gangrene |
| Dysplasia of anus (disorder) | K62.82 Dysplasia of anus |
| Encounter for adjustment and management of vascular access device | Z45.2 Encounter for adjustment and management of vascular access device |
| Encounter for general adult medical examination | Z00.00 Encounter for general adult medical examination without abnormal findings Z00.01 Encounter for general adult medical examination with abnormal findings |
| Encounter for screening of malignant neoplasm of colon | Z12.11 Encounter for screening for malignant neoplasm of colon |
| Endometriosis of pelvic peritoneum (disorder) | N80.3 Endometriosis of pelvic peritoneum |
| Enterostomy malfunction (disorder) | K94.13 Enterostomy malfunction |
| Essential (primary) hypertension | I10 Essential (primary) hypertension |
| Family history of malignant neoplasm of brain (situation) | Z80.8 Family history of malignant neoplasm of other organs or systems |
| Family history of malignant neoplasm of digestive organ (situation) | Z80.0 Family history of malignant neoplasm of digestive organs |
| Female cystocele (disorder) | N81.10 Cystocele, unspecified N81.11 Cystocele, midline N81.12 Cystocele, lateral |
| Fistula of intestine (disorder) | K63.2 Fistula of intestine |
| Fistula of stomach and duodenum | K31.6 Fistula of stomach and duodenum |
| Follicular cyst of skin and subcutaneous tissue | L72.9 Follicular cyst of the skin and subcutaneous tissue, unspecified |
| Gastric ulcer (disorder) | K25.9 Gastric ulcer, unspecified as acute or chronic, without hemorrhage or perforation |
| Gastroesophageal reflux disease without esophagitis (disorder) | K21.9 Gastro-esophageal reflux disease without esophagitis |
| Gastrointestinal hemorrhage (disorder) | K92.2 Gastrointestinal hemorrhage, unspecified |
| Gastroparesis (disorder) | K31.84 Gastroparesis |
| Gastroptosis (disorder) | K31.89 Other diseases of stomach and duodenum |
| Genital lichen sclerosus (disorder) | D07.1 Carcinoma in situ of vulva L90.0 Lichen sclerosus et atrophicus N48.0 Leukoplakia of penis
N90.4 Leukoplakia of vulva |
| Genital Molluscum contagiosum | B08.1 Molluscum contagiosum |
| Hemorrhage of anus and rectum | K62.5 Hemorrhage of anus and rectum |
| HGSIL pap smear | R87.613 High grade squamous intraepithelial lesion on cytologic smear of cervix (HGSIL) |
| Hidradenitis suppurativa (disorder) | L73.2 Hidradenitis suppurativa |
| Hidradenitis suppurativa of anus (disorder) | L73.2 Hidradenitis suppurativa |
| Idiopathic normal pressure hydrocephalus | G91.2 (Idiopathic) normal pressure hydrocephalus |
| Ileostomy status | Z93.2 Ileostomy status |
| Immune thrombocytopenic purpura | D69.3 Immune thrombocytopenic purpura |
| Infection of skin caused by Molluscum contagiosum (disorder) | B08.1 Molluscum contagiosum
H01.8 Other specified inflammations of eyelid |
| Injury of anal canal (disorder) | K64.8 Other hemorrhoids
L08.9 Local infection of the skin and subcutaneous tissue, unspecified S30.827A Blister (nonthermal) of anus, initial encounter S30.827D Blister (nonthermal) of anus, subsequent encounter S30.827S Blister (nonthermal) of anus, sequela S30.867A Insect bite (nonvenomous) of anus, initial encounter S30.867D Insect bite (nonvenomous) of anus, subsequent encounter S30.867S Insect bite (nonvenomous) of anus, sequela S36.60XA Unspecified injury of rectum, initial encounter S36.60XD Unspecified injury of rectum, subsequent encounter S36.60XS Unspecified injury of rectum, sequela |
| Intestinal volvulus (disorder) | K56.2 Volvulus |
| Intestinovesical fistula (disorder) | N32.1 Vesicointestinal fistula
N32.2 Vesical fistula, not elsewhere classified |
| Ischiorectal abscess (disorder) | K61.39 Other ischiorectal abscess |
| Jaundice (finding) | R17 Unspecified jaundice |
| Laceration of lower back without foreign body (disorder) | S31.010A Laceration without foreign body of lower back and pelvis without penetration into retroperitoneum, initial encounter
S31.010D Laceration without foreign body of lower back and pelvis without penetration into retroperitoneum, subsequent encounter S31.010S Laceration without foreign body of lower back and pelvis without penetration into retroperitoneum, sequela |
| Laceration of pelvis without foreign body (disorder) | S31.010A Laceration without foreign body of lower back and pelvis without penetration into retroperitoneum, initial encounter
S31.010D Laceration without foreign body of lower back and pelvis without penetration into retroperitoneum, subsequent encounter S31.010S Laceration without foreign body of lower back and pelvis without penetration into retroperitoneum, sequela |
| LGSIL pap smear | R87.612 Low grade squamous intraepithelial lesion on cytologic smear of cervix (LGSIL) |
| Low malignant potential (LMP) tumor of ovary | D39.10 Neoplasm of uncertain behavior of unspecified ovary
D39.11 Neoplasm of uncertain behavior of right ovary D39.12 Neoplasm of uncertain behavior of left ovary |
| Lymphadenitis (disorder) | I88.9 Nonspecific lymphadenitis, unspecified |
| Malignant neoplasm of anus | C21.0 Malignant neoplasm of anus, unspecified |
| Malignant neoplasm of body of uterus (disorder) | C54.9 Malignant neoplasm of corpus uteri, unspecified |
| Malignant neoplasm of cecum | C18.0 Malignant neoplasm of cecum |
| Malignant neoplasm of cornu of corpus uteri (disorder) | C54.9 Malignant neoplasm of corpus uteri, unspecified |
| Malignant neoplasm of endometrium | C54.1 Malignant neoplasm of endometrium |
| Malignant neoplasm of fundus of corpus uteri (disorder) | C54.3 Malignant neoplasm of fundus uteri |
| Malignant neoplasm of isthmus of uterine body (disorder) | C54.0 Malignant neoplasm of isthmus uteri |
| Malignant neoplasm of lower lobe, unspecified bronchus or lung | C34.30 Malignant neoplasm of lower lobe, unspecified bronchus or lung |
| Malignant neoplasm of myometrium of corpus uteri (disorder) | C54.2 Malignant neoplasm of myometrium |
| Malignant neoplasm of overlapping sites of unspecified female breast | C50.819 Malignant neoplasm of overlapping sites of unspecified female breast |
| Malignant neoplasm of urinary organ (disorder) | C68.8 Malignant neoplasm of overlapping sites of urinary organs
C68.9 Malignant neoplasm of urinary organ, unspecified |
| Malignant neoplasm of uterine adnexa (disorder) | C57.4 Malignant neoplasm of uterine adnexa, unspecified |
| Malignant tumor of fallopian tube (disorder) | C57.00 Malignant neoplasm of unspecified fallopian tube
C57.01 Malignant neoplasm of right fallopian tube C57.02 Malignant neoplasm of left fallopian tube |
| Malignant tumor of splenic flexure (disorder) | C18.5 Malignant neoplasm of splenic flexure |
| Melena (disorder) | K92.1 Melena |
| Molluscum contagiosum infection | B08.1 Molluscum contagiosum |
| Necrotizing fasciitis (disorder) | M72.6 Necrotizing fasciitis |
| Neoplasm of low malignant potential behavior of ovary (disorder) | D39.10 Neoplasm of uncertain behavior of unspecified ovary |
| D39.11 Neoplasm of uncertain behavior of right ovary D39.12 Neoplasm of uncertain behavior of left ovary | |
| Neoplasm of ovary (disorder) | C56.1 Malignant neoplasm of right ovary C56.2 Malignant neoplasm of left ovary C56.3 Malignant neoplasm of bilateral ovaries
C56.9 Malignant neoplasm of unspecified ovary |
| Neoplasm of uncertain behavior of anal canal (disorder) | D37.8 Neoplasm of uncertain behavior of other specified digestive organs |
| Neoplasm of uncertain behavior of anal canal and sphincter (disorder) | D37.8 Neoplasm of uncertain behavior of other specified digestive organs |
| Neoplasm of uncertain behavior of appendix (disorder) | D37.3 Neoplasm of uncertain behavior of appendix |
| Neoplasm of uncertain behavior of colon (disorder) | D37.4 Neoplasm of uncertain behavior of colon |
| Neoplasm of uncertain behavior of stomach (disorder) | D37.1 Neoplasm of uncertain behavior of stomach |
| Neoplasm of uncertain behavior of rectum (disorder) | D37.5 Neoplasm of uncertain behavior of rectum |
| Neoplasm of uncertain behavior of retroperitoneum (disorder) | D48.3 Neoplasm of uncertain behavior of retroperitoneum |
| Nontraumatic acute subdural hemorrhage | I62.01 Nontraumatic acute subdural hemorrhage |
| Nontraumatic hematoma of soft tissue (disorder) | M79.81 Nontraumatic hematoma of soft tissue |
| Nontraumatic hemoperitoneum (disorder) | K66.1 Hemoperitoneum |
| Nontraumatic intracranial hemorrhage | I62.9 Nontraumatic intracranial hemorrhage, unspecified |
| Obstructive hydrocephalus (disorder) | G91.1 Obstructive hydrocephalus |
| Outlet dysfunction constipation | K59.02 Outlet dysfunction constipation |
| Paralytic ileus (disorder) | K56.0 Paralytic ileus |
| Partial obstruction of intestine (disorder) | K56.600 Partial intestinal obstruction, unspecified as to cause
K56.690 Other partial intestinal obstruction |
| Pelvic hematoma (disorder) | M79.81 Nontraumatic hematoma of soft tissue N48.89 Other specified disorders of penis |
| Perforation of intestine (disorder) | K63.1 Perforation of intestine |
| Perianal lump (finding) | R22.2 Localized swelling, mass and lump, trunk |
| Peripheral neuropathy | G90.09 Other idiopathic peripheral autonomic neuropathy |
| Peritoneal adhesion (disorder) | K66.0 Peritoneal adhesions (postprocedural) (postinfection) |
| Personal history of colonic polyps | Z86.010 Personal history of colonic polyps |
| Pilonidal cyst with abscess | L05.01 Pilonidal cyst with abscess |
| Pouchitis | K91.850 Pouchitis |
| Primary malignant neoplasm of left ovary (disorder) | C56.2 Malignant neoplasm of left ovary |
| Primary malignant neoplasm of lower lobe, bronchus or lung (disorder) | C34.30 Malignant neoplasm of lower lobe, unspecified bronchus or lung |
| Primary malignant neoplasm of ovary (disorder) | C56.1 Malignant neoplasm of right ovary C56.2 Malignant neoplasm of left ovary C56.3 Malignant neoplasm of bilateral ovaries
C56.9 Malignant neoplasm of unspecified ovary |
| Primary malignant neoplasm of rectosigmoid junction (disorder) | C19 Malignant neoplasm of rectosigmoid junction |
| Primary malignant neoplasm of right ovary (disorder) | C56.1 Malignant neoplasm of right ovary |
| Primary malignant neoplasm of sigmoid colon (disorder) | C18.7 Malignant neoplasm of sigmoid colon |
| Primary overlapping malignant neoplasm of female left breast (disorder) | C50.812 Malignant neoplasm of overlapping sites of left female breast |
| Primary overlapping malignant neoplasm of female right breast (disorder) | C50.811 Malignant neoplasm of overlapping sites of right female breast |
| Proctodynia (finding) | K62.89 Other specified diseases of anus and rectum |
| Proctoptosis (disorder) | K62.3 Rectal prolapse |
| Prolapse of intestine (disorder) | K63.4 Enteroptosis |
| Pruritus ani (disorder) | L29.0 Pruritus ani |
| Puncture wound without foreign body, left lower leg | S81.832A Puncture wound without foreign body, left lower leg, initial encounter
S81.832D Puncture wound without foreign body, left lower leg, subsequent encounter S81.832S Puncture wound without foreign body, left lower leg, sequela |
| Puncture wound without foreign body, right lower leg | S81.831A Puncture wound without foreign body, right lower leg, initial encounter
S81.831D Puncture wound without foreign body, right lower leg, subsequent encounter S81.831S Puncture wound without foreign body, right lower leg, sequela |
| Puncture wound without foreign body, unspecified lower leg | S81.839A Puncture wound without foreign body, unspecified lower leg, initial encounter S81.839D Puncture wound without foreign body, unspecified lower leg, subsequent encounter S81.839S Puncture wound without foreign body, unspecified lower leg, sequela |
| Radiation proctitis (disorder) | K62.7 Radiation proctitis
W90.8XXA Exposure to other nonionizing radiation, initial encounter W90.8XXD Exposure to other nonionizing radiation, subsequent encounter W90.8XXS Exposure to other nonionizing radiation, sequela |
| Rectal abscess (disorder) | K61.1 Rectal abscess |
| Rectal cancer | C20 Malignant neoplasm of rectum |
| Rectal polyp (disorder) | K62.1 Rectal polyp |
| Rectocele | N81.6 Rectocele |
| Residual hemorrhoidal skin tags (disorder) | K64.4 Residual hemorrhoidal skin tags |
| Sebaceous cyst of penis (disorder) | N48.89 Other specified disorders of penis |
| Sebaceous cyst of scrotum (disorder) | L72.3 Sebaceous cyst |
| Sebaceous cyst of skin (disorder) | L72.3 Sebaceous cyst |
| Sebaceous cyst of skin of bilateral breasts (disorder) | N60.81 Other benign mammary dysplasias of right breast
N60.82 Other benign mammary dysplasias of left breast N60.89 Other benign mammary dysplasias of unspecified breast |
| Sebaceous cyst of skin of breast (disorder) | N60.81 Other benign mammary dysplasias of right breast
N60.82 Other benign mammary dysplasias of left breast N60.89 Other benign mammary dysplasias of unspecified breast |
| Skin lesion (disorder) | L98.9 Disorder of the skin and subcutaneous tissue, unspecified |
| Stenosis of anal canal (disorder) | K62.4 Stenosis of anus and rectum |
| Stenosis of rectum (disorder) | K62.4 Stenosis of anus and rectum |
| Stenosis of rectum and anus (disorder) | K62.4 Stenosis of rectum and anus |
| Subacute non-traumatic intracranial subdural hemorrhage | I62.01 Nontraumatic subacute subdural hemorrhage |
| Thrombocytopenia, unspecified | D69.6 Thrombocytopenia, unspecified |
| Unspecified B-cell lymphoma | C85.10 Unspecified B-cell lymphoma, unspecified site C85.11 Unspecified B-cell lymphoma, lymph nodes of head, face, and neck
C85.12 Unspecified B-cell lymphoma, intrathoracic lymph nodes C85.13 Unspecified B-cell lymphoma, intra-abdominal lymph nodes C85.14 Unspecified B-cell lymphoma, lymph nodes of axilla and upper limb C85.15 Unspecified B-cell lymphoma, lymph nodes of inguinal region and lower limb C85.16 Unspecified B-cell lymphoma, intrapelvic lymph nodes C85.17 Unspecified B-cell lymphoma, spleen C85.18 Unspecified B-cell lymphoma, lymph nodes of multiple sites C85.19 Unspecified B-cell lymphoma, extranodal and solid organ sites C85.20 Mediastinal (thymic) large B-cell lymphoma, unspecified site |
| Unspecified closed fracture of lumbar vertebra | S32.009A Unspecified fracture of unspecified lumbar vertebra, initial encounter for closed fracture S32.009D Unspecified fracture of unspecified lumbar vertebra, subsequent encounter for fracture with routine healing
S32.009G Unspecified fracture of unspecified lumbar vertebra, subsequent encounter for fracture with delayed healing S32.009K Unspecified fracture of unspecified lumbar vertebra, subsequent encounter for fracture with nonunion S32.009S Unspecified fracture of unspecified lumbar vertebra, sequela |
| Unspecified closed fracture of unspecified forearm | S52.90XA Unspecified fracture of unspecified forearm, initial encounter for closed fracture S52.90XD Unspecified fracture of unspecified forearm, subsequent encounter for closed fracture with routine healing
S52.90XG Unspecified fracture of unspecified forearm, subsequent encounter for closed fracture with delayed healing S52.90XK Unspecified fracture of unspecified forearm, subsequent encounter for closed fracture with nonunion S52.90XP Unspecified fracture of unspecified forearm, subsequent encounter for closed fracture with malunion S52.90XS Unspecified fracture of unspecified forearm, sequela |
| Vaginal enterocele (disorder) | N81.5 Vaginal enterocele |
| Vascular disorder of intestine (disorder) | K55.9 Vascular disorder of intestine, unspecified |
| Ventral hernia without obstruction or gangrene | K43.9 Ventral hernia without obstruction or gangrene |
| Vulval pain (finding) | N94.818 Other vulvodynia N94.819 Vulvodynia, unspecified |
| Vulvodynia (disorder) | N94.818 Other vulvodynia N94.819 Vulvodynia, unspecified |
| Wound (disorder) | T14.8XXA Other injury of unspecified body region, initial encounter
T14.8XXD Other injury of unspecified body region, subsequent encounter T14.8XXS Other injury of unspecified body region, sequela |
Appendix B
Regimen Consolidation Summary
Updates
The following regimens have been created as part of the Reference/Biosimilar Merge initiative.
- Bevacizumab (5 mg/kg) Q14D (Colon, Rectal) (Addition to Chemotherapy)
- Bevacizumab (7.5 mg/kg) Q21D (Colon, Rectal) (Addition to Chemotherapy)
- Bevacizumab (15 mg/kg) + Erlotinib Q21D
- Bevacizumab (15 mg/kg) Q21D
- Bevacizumab D1,15 + Cyclophosphamide PO Q28D
- Bevacizumab D1,15 Q28D
- Bevacizumab Q14D (RCC)
- Capecitabine D1-14 + Bevacizumab Q21D
- Capecitabine D1-14 + Irinotecan (XELIRI/CAPIRI) + Bevacizumab Q21D
- Capecitabine D1-14 + Oxaliplatin (XELOX/CAPOX) + Bevacizumab Q21D
- Carboplatin + Liposomal Doxorubicin + Bevacizumab D1,15 Q28D
- Darbepoetin alfa Q28D (Chronic Kidney Disease not on Dialysis)
- Fluorouracil (Bolus + CIV) D1-2 + Leucovorin (Simplified) + Bevacizumab Q14D
- Fluorouracil (Bolus + CIV) D1-2 + Leucovorin + Irinotecan (FOLFIRI) + Bevacizumab Q14D
- Fluorouracil (Bolus + CIV) D1-2 + Leucovorin + Oxaliplatin (FOLFOX 6, Modified) + Bevacizumab Q14D
- Fluorouracil (Bolus + CIV) D1-2 + Leucovorin D1-2 (De Gramont) + Bevacizumab Q14D
- Fluorouracil Bolus D1,8,15,22,29,36 + Leucovorin D1,8,15,22,29,36 (Roswell Park) + Bevacizumab D1,15,29,43 Q56D
- Fluorouracil Bolus D1-5 + Leucovorin D1-5 (Mayo) + Bevacizumab D1,15 Q28D
- FOLFIRINOX (Modified) + Bevacizumab Q14D
- FOLFIRINOX + Bevacizumab Q14D
- FOLFOXIRI + Bevacizumab Q14D
- Gemcitabine D1,8 + Carboplatin + Bevacizumab Q21D
- Irinotecan + Bevacizumab Q14D
- Leuprolide Q28D (Breast Cancer)
- Liposomal Doxorubicin + Bevacizumab D1,15 Q28D
- Luspatercept-aamt Q21D (MDS)
- Olaparib + Bevacizumab Q21D
- Paclitaxel + Carboplatin (AUC 5) + Bevacizumab (15 mg/kg) Q21D (Ovarian)
- Paclitaxel + Carboplatin (AUC 6) + Bevacizumab (7.5 mg/kg) Q21D (Ovarian)
- Paclitaxel + Carboplatin (AUC 6) + Bevacizumab (15 mg/kg) Q21D (Ovarian)
- Paclitaxel + Carboplatin + Bevacizumab (7.5 mg/kg) Q21D (Bevacizumab Continuation, Ovarian)
- Paclitaxel + Carboplatin + Bevacizumab (15 mg/kg) Q21D (Bevacizumab Continuation, Ovarian)
- Paclitaxel + Carboplatin + Bevacizumab Q21D (Cervical)
- Paclitaxel + Carboplatin + Bevacizumab Q21D (NSCLC)
- Paclitaxel + Cisplatin + Bevacizumab Q21D
- Paclitaxel + Topotecan D1-3 + Bevacizumab Q21D
- Paclitaxel D1,8,15,22 + Bevacizumab D1,15 Q28D (Ovarian)
- Pembrolizumab + Paclitaxel + Carboplatin + Bevacizumab Q21D (Cervical)
- Pembrolizumab + Paclitaxel + Cisplatin + Bevacizumab Q21D (Cervical)
- Pemetrexed + Bevacizumab (15 mg/kg) Q21D (Maintenance)
- Pemetrexed + Carboplatin + Bevacizumab Q21D
- Pemetrexed + Cisplatin + Bevacizumab Q21D (Mesothelioma)
- Topotecan D1,8,15 + Bevacizumab D1,15 Q28D
- Topotecan D1-5 + Bevacizumab Q21D
- Trifluridine/Tipiracil D1-5, D8-12 + Bevacizumab D1,15 Q28D
Removals
The following regimens have been inactivated as part of the Reference Regimen / Biosimilar Merge initiative.
- Atezolizumab + Bevacizumab + Paclitaxel + Carboplatin Q21D (Part 1 of 2: Induction) Reference
- Atezolizumab + Bevacizumab + Paclitaxel + Carboplatin Q21D (Part 2 of 2: Atezolizumab + Bevacizumab Maintenance) Reference
- Atezolizumab + Bevacizumab BIOSIMILAR + Paclitaxel + Carboplatin Q21D (Part 1 of 2: Induction
- Atezolizumab + Bevacizumab BIOSIMILAR + Paclitaxel + Carboplatin Q21D (Part 2 of 2: Atezolizumab + Bevacizumab Maintenance)
- Atezolizumab + Bevacizumab BIOSIMILAR Q21D
- Atezolizumab + Bevacizumab Q21D Reference
- Bevacizumab (15 mg/kg) + Erlotinib Q21D Reference
- Bevacizumab (15 mg/kg) BIOSIMILAR + Erlotinib Q21D)
- Bevacizumab (15 mg/kg) BIOSIMILAR Q21D
- Bevacizumab (15 mg/kg) Q21D Reference
- Bevacizumab (5 mg/kg) BIOSIMILAR Q14D (Colon, Rectal) (Addition to Chemotherapy)
- Bevacizumab (7.5 mg/kg) BIOSIMILAR Q21D (Colon, Rectal) (Addition to Chemotherapy)
- Bevacizumab BIOSIMILAR D1,15 + Cyclophosphamide PO Q28D
- Bevacizumab BIOSIMILAR D1,15 Q28D
- Bevacizumab BIOSIMILAR Q14D (RCC)
- Bevacizumab D1,15 + Cyclophosphamide PO Q28D Reference
- Bevacizumab D1,15 Q28D Reference
- Bevacizumab Q14D (RCC) Reference
- Capecitabine D1-14 + Bevacizumab BIOSIMILAR Q21D
- Capecitabine D1-14 + Bevacizumab Q21D Reference
- Capecitabine D1-14 + Irinotecan (XELIRI/CAPIRI) + Bevacizumab BIOSIMILAR Q21D
- Capecitabine D1-14 + Irinotecan (XELIRI/CAPIRI) + Bevacizumab Q21D Reference
- Capecitabine D1-14 + Oxaliplatin (XELOX/CAPOX) + Bevacizumab BIOSIMILAR Q21D
- Capecitabine D1-14 + Oxaliplatin (XELOX/CAPOX) + Bevacizumab Q21D Reference
- Carboplatin + Liposomal Doxorubicin + Bevacizumab BIOSIMILAR D1,15 Q28D
- Carboplatin + Liposomal Doxorubicin + Bevacizumab D1,15 Q28D Reference
- Darbepoetin alfa Q28D (CKD not on Dialysis)
- Fluorouracil (Bolus + CIV) D1-2 + Leucovorin (Simplified) + Bevacizumab Q14D Reference
- Fluorouracil (Bolus + CIV) D1-2 + Leucovorin (Simplified) + Bevacizumab BIOSIMILAR Q14D
- Fluorouracil (Bolus + CIV) D1-2 + Leucovorin + Irinotecan (FOLFIRI) + Bevacizumab Q14D Reference
- Fluorouracil (Bolus + CIV) D1-2 + Leucovorin + Irinotecan (FOLFIRI) + Bevacizumab BIOSIMILAR Q14D
- Fluorouracil (Bolus + CIV) D1-2 + Leucovorin + Oxaliplatin (FOLFOX 6, Modified) + Bevacizumab Q14D Reference
- Fluorouracil (Bolus + CIV) D1-2 + Leucovorin + Oxaliplatin (FOLFOX 6, Modified) + Bevacizumab BIOSIMILAR Q14D
- Fluorouracil (Bolus + CIV) D1-2 + Leucovorin D1-2 (De Gramont) + Bevacizumab Q14D Reference
- Fluorouracil (Bolus + CIV) D1-2 + Leucovorin D1-2 (De Gramont) + Bevacizumab BIOSIMILAR Q14D
- Fluorouracil Bolus D1,8,15,22,29,36 + Leucovorin D1,8,15,22,29,36 (Roswell Park) + Bevacizumab D1,15,29,43 Q56D Reference
- Fluorouracil Bolus D1,8,15,22,29,36 + Leucovorin D1,8,15,22,29,36 (Roswell Park) + Bevacizumab BIOSIMILAR D1,15,29,43 Q56D
- Fluorouracil Bolus D1-5 + Leucovorin D1-5 (Mayo) + Bevacizumab BIOSIMILAR D1,15 Q28D
- Fluorouracil Bolus D1-5 + Leucovorin D1-5 (Mayo) + Bevacizumab D1,15 Q28D Reference
- FOLFIRINOX (Modified) + Bevacizumab BIOSIMILAR Q14D
- FOLFIRINOX (Modified) + Bevacizumab Q14D Reference
- FOLFIRINOX + Bevacizumab BIOSIMILAR Q14D
- FOLFIRINOX + Bevacizumab Q14D Reference
- FOLFOXIRI + Bevacizumab BIOSIMILAR Q14D
- FOLFOXIRI + Bevacizumab Q14D Reference
- Gemcitabine D1,8 + Carboplatin + Bevacizumab BIOSIMILAR Q21D
- Gemcitabine D1,8 + Carboplatin + Bevacizumab Q21D Reference
- Irinotecan + Bevacizumab BIOSIMILAR Q14D
- Irinotecan + Bevacizumab Q14D Reference
- Leuprolide Q28D (Breast)
- Liposomal Doxorubicin + Bevacizumab BIOSIMILAR D1,15 Q28D
- Liposomal Doxorubicin + Bevacizumab D1,15 Q28D Reference
- Luspatercept-aamt Q21D (MDS, Myelofibrosis)
- Olaparib + Bevacizumab BIOSIMILAR Q21D
- Olaparib + Bevacizumab Q21D Reference
- Paclitaxel + Carboplatin (AUC 5) + Bevacizumab (15 mg/kg) BIOSIMILAR Q21D (Ovarian)
- Paclitaxel + Carboplatin (AUC 5) + Bevacizumab (15 mg/kg) Q21D (Ovarian) Reference
- Paclitaxel + Carboplatin (AUC 6) + Bevacizumab (15 mg/kg) BIOSIMILAR Q21D (Ovarian)
- Paclitaxel + Carboplatin (AUC 6) + Bevacizumab (15 mg/kg) Q21D (Ovarian) Reference
- Paclitaxel + Carboplatin (AUC 6) + Bevacizumab (7.5 mg/kg) BIOSIMILAR Q21D (Ovarian)
- Paclitaxel + Carboplatin (AUC 6) + Bevacizumab (7.5 mg/kg) Q21D (Ovarian) Reference
- Paclitaxel + Carboplatin + Bevacizumab (15 mg/kg) BIOSIMILAR Q21D (Bevacizumab Continuation, Ovarian)
- Paclitaxel + Carboplatin + Bevacizumab (15 mg/kg) Q21D (Bevacizumab Continuation, Ovarian) Reference
- Paclitaxel + Carboplatin + Bevacizumab (7.5 mg/kg) BIOSIMILAR Q21D (Bevacizumab Continuation, Ovarian)
- Paclitaxel + Carboplatin + Bevacizumab (7.5 mg/kg) Q21D (Bevacizumab Continuation, Ovarian) Reference
- Paclitaxel + Carboplatin + Bevacizumab BIOSIMILAR Q21D (Cervical)
- Paclitaxel + Carboplatin + Bevacizumab BIOSIMILAR Q21D (NSCLC)
- Paclitaxel + Carboplatin + Bevacizumab Q21D (Cervical) Reference
- Paclitaxel + Carboplatin + Bevacizumab Q21D (NSCLC) Reference
- Paclitaxel + Cisplatin + Bevacizumab BIOSIMILAR Q21D
- Paclitaxel + Cisplatin + Bevacizumab Q21D Reference
- Paclitaxel + Topotecan D1-3 + Bevacizumab BIOSIMILAR Q21D
- Paclitaxel + Topotecan D1-3 + Bevacizumab Q21D Reference
- Paclitaxel D1,8,15,22 + Bevacizumab BIOSIMILAR D1,15 Q28D (Ovarian)
- Paclitaxel D1,8,15,22 + Bevacizumab D1,15 Q28D (Ovarian) Reference
- Pembrolizumab + Paclitaxel + Carboplatin + Bevacizumab BIOSIMILAR Q21D (Cervical)
- Pembrolizumab + Paclitaxel + Carboplatin + Bevacizumab Q21D (Cervical) Reference
- Pembrolizumab + Paclitaxel + Cisplatin + Bevacizumab BIOSIMILAR Q21D (Cervical)
- Pembrolizumab + Paclitaxel + Cisplatin + Bevacizumab Q21D (Cervical) Reference
- Pemetrexed + Bevacizumab (15 mg/kg) BIOSIMILAR Q21D (Maintenance)
- Pemetrexed + Bevacizumab (15 mg/kg) Q21D (Maintenance) Reference
- Pemetrexed + Carboplatin + Bevacizumab BIOSIMILAR Q21D
- Pemetrexed + Carboplatin + Bevacizumab Q21D Reference
- Pemetrexed + Cisplatin + Bevacizumab BIOSIMILAR Q21D (Mesothelioma)
- Pemetrexed + Cisplatin + Bevacizumab Q21D (Mesothelioma) Reference
- Topotecan D1,8,15 + Bevacizumab BIOSIMILAR D1,15 Q28D
- Topotecan D1-5 + Bevacizumab BIOSIMILAR Q21D
- Topotecan D1-5 + Bevacizumab Q21D Reference
- Trifluridine/Tipiracil D1-5, D8-12 + Bevacizumab BIOSIMILAR D1,15 Q28D
- Trifluridine/Tipiracil D1-5, D8-12 + Bevacizumab D1,15 Q28D Reference